Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease.

ABSTRACT:

Background

The recent promise of disease-modifying therapies for Alzheimer's disease (AD) has reinforced the need for accurate biomarkers for early disease detection, diagnosis and treatment monitoring. Advances in the development of novel blood-based biomarkers for AD have revealed that plasma levels of tau phosphorylated at various residues are specific and sensitive to AD dementia. However, the currently available tests have shortcomings in access, throughput, and scalability that limit widespread implementation.

Methods

We evaluated the diagnostic and prognostic performance of a high-throughput and fully-automated Lumipulse plasma p-tau181 assay for the detection of AD. Plasma from older clinically unimpaired individuals (CU, n = 463) and patients with mild cognitive imp

SUBMITTER: Wilson EN 

PROVIDER: S-EPMC9652927 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature